Vyvanse and Pregnancy
At this time, there have been no animal or human studies conducted on Vyvanse and pregnancy. However, other medications that are very similar to Vyvanse have been shown to increase the risk of birth defects and miscarriages when given to pregnant women in very high doses. Therefore, the FDA has classified Vyvanse as a pregnancy Category C medication, meaning it may not be safe for use during pregnancy.
Vyvanse™ (lisdexamfetamine dimesylate) may not be safe for pregnant women, because little is known about the risks of using it during pregnancy.
The U.S. Food and Drug Administration (FDA) uses a pregnancy category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category C is given to medicines that have not been studied in pregnant humans, but do appear to cause harm to the fetus in animal studies. Also, medicines that have not been studied in any pregnant women or animals are automatically given a pregnancy Category C rating.
Vyvanse was classified as a pregnancy Category C medication because it has not been studied in any pregnant women or animals. However, other amphetamine medications that are very similar to Vyvanse have been shown to increase the risk of birth defects and miscarriages when given to pregnant women in very high dosages. There is also some evidence (from animal studies) that taking amphetamines during pregnancy may lead to long-term behavior problems in the offspring.
If you are pregnant or thinking about becoming pregnant, let your healthcare provider know. Your healthcare provider will consider both the benefits and risks of using Vyvanse during pregnancy before making a recommendation for your particular situation.